


Investor Fact Sheet

First half-year 2024/25


(Unaudited Swiss GAAP FER figures)
in thousand CHF

	Half-year 2024/25	in %	Half-year 2023/24	in %	Change	in %
Sales of goods and services group	324.0	100.0	255.4	100.0	68.6	26.9
thereof continued business group	308.1	95.1	237.2	92.9	70.9	29.9
Ypsomed Delivery Systems (YDS)	220.3	68.0	176.5	69.1	43.8	24.8
Ypsomed Diabetes Care (YDC)	98.1	30.3	72.6	28.4	25.6	35.2
thereof continued business YDC	82.3	25.4	54.4	21.3	27.9	51.3
Others	5.5	1.7	6.3	2.5	-0.7	-11.6
Gross profit	117.4	36.2	87.8	34.4	29.6	33.7
Operating profit	40.5	12.5	39.9	15.6	0.6	1.6
thereof continued business group	65.3	20.1	45.5	17.8	19.8	43.4
Financial income	2.1	0.7	2.6	1.0	-0.5	-17.8
Financial expenses	-6.3	-2.0	-4.2	-1.7	-2.1	50.4
Income taxes	-3.7	-1.1	-1.7	-0.7	-2.0	119.5
Net profit	32.6	10.1	36.6	14.3	-4.0	-10.9
Earnings per share (undiluted) in CHF	2.39		2.68		-0.29	-10.9
Operating profit	40.5	12.5	39.9	15.6	0.6	1.6
Depreciation and impairment of fixed assets	23.2		20.5		2.7	12.9
Amortisation and impairment of intangible assets	14.1		15.4		-1.3	-8.7
EBITDA (operating profit before depreciation and amortisation)	77.8	24.0	75.8	29.7	1.9	2.5
thereof continued business group	100.9	31.1	79.0	30.9	21.9	27.7
Equity ratio in %	52.7%		56.1% ¹		-3.4%	
Investments in fixed assets	93.8		51.1		48.4	96.6
Investments in intangible assets	38.1		39.5		-0.4	-1.1
Number of employees (headcount)	2592		2389 ¹		203	8.5
Full-time equivalents	2495		2296 ¹		199	8.7

Turnover at group level



EBIT at group level



¹ As of 31 March 2024

² DiaExpert GmbH was divested on 31 December 2022. This only affects the financial year 2022/23.

³ The pen needle and BGM business were sold on 31 July 2024.

Further information on significant shareholders and shareholder groups as well as other financial figures of the Ypsomed Group are available in the Semiannual Report 2023/24 and on www.ypsomed.ch.

Legal disclaimer: The information contained in this document has not been independently verified and no representation or warranty, expressed or implied, is made to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained herein. Neither Ypsomed Holding AG, its advisors or representatives, nor their respective affiliates shall have any liability whatsoever for any loss whatsoever arising from any use of this document, or its content, or otherwise arising in connection with this document. This document does not constitute, or form part of, an offer to sell or a solicitation of an offer to purchase any shares and neither it nor any part of it shall form the basis of, or be relied upon in connection with, any contract or commitment whatsoever. This document contains forward-looking statements which involve risks and uncertainties. These statements may be identified by such words as “may”, “plans”, “expects”, “believes” and similar expressions, or by their context. These statements are made on the basis of current knowledge and assumptions. Various factors could cause actual future results, performance or events to differ materially from those described in these statements. No obligation is assumed to update any forward-looking statements.